TG Therapeutics TGTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $616.29M+87.3% | $329M+40.8% | $233.66M+8,293% | $2.78M-58.4% | ||
| $100.71M+162% | $38.49M+172% | $14.13M— | —— | ||
| $515.57M+77.5% | $290.52M+32.3% | $219.53M— | —— | ||
| 83.7%-4.6pp | 88.3%-5.6pp | 94%— | —— | ||
| $160.22M+69.9% | $94.29M+23.7% | $76.19M-39.2% | $125.35M-43.7% | ||
| $232.03M+50.4% | $154.3M+25.7% | $122.71M+28.5% | $95.48M-25.5% | ||
| $183.98M+49.7% | $122.92M-21.5% | $156.66M-19.9% | $195.62M-44.3% | ||
| $492.96M+71.7% | $287.08M+34.8% | $213.03M— | —— | ||
| $123.32M+194% | $41.93M— | —— | -$218.32M+36.7% | ||
| 20%+7.3pp | 12.7%— | —— | -7,841.8%-2,688pp | ||
| $26.73M+10.6% | $24.16M+91.5% | $12.62M+23.8% | $10.19M+80.8% | ||
| -$15.93M+2.5% | -$16.34M-116% | -$7.57M-37.7% | -$5.5M-65.0% | ||
| —— | -$4.61M— | —— | $0— | ||
| $107.39M+320% | $25.59M— | —— | -$223.81M+35.7% | ||
| -$361.85M-16,466% | $2.21M+467% | $390K— | $0— | ||
| $447.18M+1,812% | $23.38M— | —— | -$223.81M+35.7% | ||
| 72.6%+65.5pp | 7.1%— | —— | -8,039.2%-2,835pp | ||
| $2.78+1,886% | $0.14— | —— | -$1.64+37.6% | ||
| $3.11+1,729% | $0.17— | —— | -$1.64+37.6% | ||
| 647.7M+3.4% | 626.7M+6.9% | 586.2M+8.6% | 539.9M+2.2% | ||
| 583.2M+0.3% | 581.4M+2.6% | 566.6M+4.9% | 539.9M+2.2% | ||
| $16.62M+48.9% | $11.16M-14.2% | $13.01M-1.6% | $13.23M-45.0% | ||
| $48.05M+53.1% | $31.38M+25.9% | $24.92M-20.7% | $31.44M-15.6% | ||
| $10.79M+38.0% | $7.82M+55.1% | $5.04M— | —— | ||
| $143.6M+72.7% | $83.13M+31.6% | $63.18M-43.7% | $112.13M-43.5% | ||
| $616.29M+87.3% | $329M+40.8% | $233.66M+8,293% | $2.78M-58.4% | ||
| $123.32M+194% | $41.93M— | —— | -$218.32M+36.7% | ||
| $123.38M+194% | $42M— | —— | -$218.01M+36.7% | ||
| $123.38M+194% | $42M— | —— | -$218.01M+36.7% | ||
| 20%+7.3pp | 12.8%— | —— | -7,830.9%-2,681pp | ||
| $123.32M+194% | $41.93M— | —— | -$218.32M+36.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is TG Therapeutics's revenue?
- TG Therapeutics (TGTX) generated $700.3M in revenue over the trailing twelve months, up 81.3% year over year.
- Is TG Therapeutics profitable?
- TG Therapeutics reported $461.9M in net income over the trailing twelve months, a 66.0% net margin.
- What are TG Therapeutics's profit margins?
- Gross margin is 83.1% and operating margin is 21.3%, with a 66.0% net margin.
- What is TG Therapeutics's earnings per share?
- TG Therapeutics's diluted EPS over the trailing twelve months is $2.87.
- Where does TG Therapeutics's income statement data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
